Skip to main content
. 2021 Sep 13;12:707298. doi: 10.3389/fimmu.2021.707298

Figure 7.

Figure 7

Schematic illustration of the anti-tumor immune responses triggered by ubiquitinated protein-4T1/epirubicin nanovaccine combined with stimulator of interferon gene agonists.